HLS Therapeutics Inc. (TSE:HLS – Get Free Report) shares hit a new 52-week low during trading on Monday . The company traded as low as C$3.00 and last traded at C$3.12, with a volume of 1205 shares trading hands. The stock had previously closed at C$3.10.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on HLS shares. Stifel Nicolaus dropped their target price on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th. Raymond James dropped their price objective on HLS Therapeutics from C$5.00 to C$4.00 in a research note on Friday, May 10th.
HLS Therapeutics Stock Performance
About HLS Therapeutics
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Recommended Stories
- Five stocks we like better than HLS Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- With Risk Tolerance, One Size Does Not Fit All
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- How to Read Stock Charts for Beginners
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.